1232 22nd Street N.W. Washington, D.C. 20037-1202 (202) 223.2226 1 (800) 231.4222

8th ISO 8th International Symposium on Osteoporosis: Translating Research into Clinical Practice April 1 – 5, 2009 Marriott Wardman Park Hotel, Washington, DC Click here for Continuing Education Certificates - Deadline to Access June 06, 2009 Click here to purchase ISO8 audio recordings Symposium Purpose Overall Outcome Objectives Target Audience Preliminary Program CE Information Exhibits Exhibitor List Networking Events Corporate Supporters Information for the Press Symposium Purpose The National Osteoporosis Foundation (NOF)-sponsored International Symposium on Osteoporosis (ISO) is designed to provide the most current and clinically relevant evidence-based information on the prevention, diagnosis, and treatment of osteoporosis.  This will be accomplished through in-depth educational sessions addressing primary and secondary osteoporosis, clinical considerations and therapeutics, socio-behavioral medicine, nutrition, education, epidemiology, pathophysiology, genetics and emerging science. In the U.S. today, ten million individuals already have osteoporosis and 34 million more have low bone mass, placing them at increased risk for the disease and related fractures.  One in two women and one in four men age 50 and older are at risk for an osteoporosis-related fracture in their lifetime.  The disease affects people of all ethnic backgrounds.  Increased life expectancy puts greater numbers at risk for osteoporosis, the need for early and accurate diagnosis becomes more critical.  While osteoporosis can be reliably diagnosed, treated and prevented if often goes undetected in patients, leading to severe physical, social, functional and psychological consequences including increased mortality and morbidity.  Thus, improving the diagnosis and treatment of osteoporosis is a major challenge and priority for healthcare professionals.  The programs that comprise the 8th International Symposium stress the practical application of science and research to the clinical management of patients with osteoporosis and low bone mass. Overall Outcome Objectives After participating in this International Symposium on Osteoporosis participants should be able to: Appreciate the significant threat of osteoporosis through the latest epidemiology of the disease Comprehend the physiology and genetics of osteoporosis in order to improve diagnosis and treatment Perform appropriate clinical assessments to determine potential presence of secondary osteoporosis Determine treatment options that consider both the secondary conditions and the osteoporosis Apply clinical decision-making tools for osteoporosis management within the medical practice environment Differentiate among  FDA-approved medications and select appropriate therapies as indicated Utilize primary, secondary and tertiary treatment modalities for osteoporosis across the continuum of care Develop patient and consumer education programs within their practice and community Take advantage of available resources that can impact bone health and quality of life Comprehend emerging discoveries and their affect on the future of osteoporosis care Target Audience This scientific program is designed for healthcare professionals with an interest in osteoporosis and bone health across the lifespan, including those working in family practice, endocrinology, rheumatology, obstetrics/gynecology, radiology, physical and occupational therapy and research. These include: Physicians Nurses Nurse Practitioners Physician Assistants Dietetians Radiology Technicians Physical and Occupational Therapists Pharmacists   Preliminary Program (as of February 2009) Wednesday, April 1, 2009 2:00 p.m. Hands on Workshops Using Fracture Risk Assessment in Your Practice, Marjorie Luckey, MD  Pharmacological Treatments for Osteoporosis: Past, Present and Future, E. Michael Lewiecki, MD Thursday, April 2, 2009 8:00 a.m. Lessons from Space Travel for Improving Bone Health on Earth, Peter Cavanagh, PhD 9:30 a.m. Poster Presentations and Exhibit Hall Break 10:30 a.m. Plenary Osteoporosis: Secondary Causes of Bone Loss Determining Secondary Causes of Osteoporosis, Marjorie Luckey, MD Thyroid Disease and Bone Loss, David Cooper, MD Chronic Kidney Disease and Bone Health, Paul Miller, MD 1:15 p.m. Plenary Identification and Management of Osteoporosis: Maximizing the Utility of DXA and Risk Factors Use of Biochemical Markers in Osteoporosis Management, Michael Kleerekoper, MD Interpreting the DXA Report and Vertebral Fracture Assessment, E. Michael Lewiecki, MD Utilizing Risk Factors in Assessing Fracture Risk and Targeting Treatment, Ethel Siris, MD 3:00 p.m. Concurrent Sessions Premenopausal Skeletal Development Prenatal and Early Postnatal Skeletal Development, Winston Koo, MD Adolescent Skeleton, Catherine Gordon, MD Relationships between Birth Control, Depo Provera, Pregnancy, Lactation and Bone Health, MaryFran Sowers, MD Osteoporosis in Men Diagnosis, Treatment, Risk Factors and the NOF Clinical Guidelines for Men  with Osteoporosis, Eric Orwoll, MD Male Spinal Cord Injury and Bone, Robert Adler, MD Determinants of Initiation and Continuation of Antiresorptive Therapy            Role of Primary Care for Osteoporosis Management, Vernon J. Hershberger, MD      How and How Long to Treat Osteoporosis, Juliet Compston, MD The Positive Role of Exercise in Good Posture, Safe Body Mechanics, and Return to Function After Fracture Posture and Body Mechanics, Carleen Lindsey, PT Exercise to Return to Function After Vertebral Fracture, Kathy Shipp, PT Post Hip Fracture Care, Jay Magaziner, PhD New Concepts in the Physiology of Skeletal Health             Pathogenetic Mechanisms in Bone Loss, Lawrence Raisz, MD             Genetics of Bone, Joseph Zmuda, PhD Friday, April 3, 2009 8:00 a.m.  Plenary Osteoporosis: Diseases and Bone Loss             Osteoporosis and the Bowel: What’s the Link?, Peter Green, MD             Renal Calculi, Hypercalcemia and Hypercalciuria, Murray Favus, MD             Weight Loss, Bariatric Surgery and Bone, Jeffrey Mechanick, MD             Eating Disorders and Bone Loss, Madhu Misra, MD 9:45 a.m. Poster Presentations and Exhibit Hall Break 10:45 a.m. Meet the Professor Sessions Premenopausal Women, Elizabeth Shane, MD Kyphoplasty and Vertebroplasty, Mary E. Jensen, MD Fundamentals and Pitfalls of DXA Interpreting: Physician and Technologist Interactive Session, Nelson Watts, MD and JoAnn Caudill, RT Patient and Professional Education in Osteoporosis, Daniel Solomon, MD Nutrition and Osteoporosis, Connie Weaver, PhD 1:00 p.m. Plenary Non-Pharmacological Issues in Osteoporosis Management I             Calcium and Vitamin D, Bess Dawson-Hughes, MD             Exercise Prescription for Osteoporosis, Karen Kemmis, DPT             Osteoporosis Treatments: Compliance and Persistence, Deborah T. Gold, PhD             Nutraceuticals: Effects on Bone Metabolism, Jeri Nieves, PhD 2:45 p.m. Plenary Osteoporosis: Medication, Disease and Bone Loss             Cancer Therapy-Induced Bone Loss in Women, Robert Gagel, MD             Cancer Therapy-Induced Bone Loss in Men, Susan Greenspan, MD             Glucocorticoid-Induced Bone Loss, Kenneth Saag, MD             PPIs, Anticoagulants and Antiseizure Medications and Bone Loss, Mary Beth                     O’Connell, PharmD 4:30 p.m. Plenary Coalition for a National Action Plan on Bone Health: Bone Summit Panel Discussion             Panelists:             Leo Schargorodski             Joan McGowan, PhD             Robert Gagel, MD Saturday, April 4, 2009 8:00 a.m. Plenary Disease and Therapy-Induced Bone Loss             Diabetes and Its Treatment: Outcomes for Bone, John Bilezikian, MD             Stroke, Parkinson’s Disease and Bone Health, F. Michael Gloth III, MD             Depression and Bone, Jonathan D. Adachi, MD             Rheumatoid Arthritis and Connective Tissue Disease: Their Impact on Bone, Chad Deal, MD 9:45 a.m. Poster Presentations and Exhibit Hall Break  10:45 a.m. Meet the Professor Sessions Premenopausal Women, Elizabeth Shane, MD Kyphoplasty and Vertebroplasty, Mary E. Jensen, MD Fundamentals and Pitfalls of DXA Interpreting: Physician and Technologist Interactive Session, Nelson Watts, MD and JoAnn Caudill, RT Low Peak Bone Mass: When is it Real and When a Fiction?, Robert Lindsay, MD, PhD Nutrition and Osteoporosis, Connie Weaver, PhD  1:00 p.m. Plenary Non-Pharmacological Issues in Osteoporosis Management II             Fall Prevention, Stephanie Studenski, MD             Osteoporosis in the Long Term Care Setting, Douglas Kiel, MD             Osteoporosis and Its Effect on Quality of Life, Stuart Silverman, MD 2:45 p.m. Case Studies Early Postmenopausal Women and Bone, Margery Gass, MD Role of Advanced Practice Clinicians (NPs and PAs) in Prevention and Identification of Osteoporosis, Adrienne Berarducci, PhD, ARNP and Rick Pope, PA-C Subtrochanteric and Stress Fractures,  Joseph Lane, MD Sunday, April 5, 2009 8:00 a.m. Plenary FDA-Approved Therapies for Osteoporosis             Bisphosphonates for Osteoporosis: Current Uses and Challenges, Steven Harris, MD             Anabolic Therapy for Osteoporosis, Felicia Cosman, MD             Hormonal Therapies for Osteoporosis: Estrogen, Calcitonin and EEAs (SERMs), Robert Lindsay, MD, PhD             Treatment of Osteoporosis in the Setting of Hypogonadism: Use of Testosterone and             Other Agents, Benjamin Leder, MD 10:15 a.m. Plenary Emerging Therapies and Diagnostic Techniques             Bone Quality: New Imaging to Refine Fracture Risk and Improve Therapy, Mary Bouxsein, PhD and David Dempster, PhD             Emerging Pharmaceutical Therapies: Denosumab and New EEAs, Michael McClung, MD     Continuing Education The 8th International Symposium on Osteoporosis: Translating Research into Clinical Practice has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). Physicians: The National Osteoporosis Foundation designates this educational activity for a maximum of 26.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians Assistants: This program has been reviewed and is approved for a maximum of 26.5 hours of AAPA Category I CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Live Programs and for Commercial Support of Live Programs. Nurses: This continuing nursing education activity was approved by the Virginia Nurses' Association Continuing Education Approval Committee, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.) Nurse Practitioners: This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health for 26.5 contact hours of continuing education credit including 13.0 hours of pharmacology credit. NPWH Activity number 09-02. Each participant should claim only those contact hours that he/she actually spent in the educational activity. Other Healthcare Professionals: Certificates of Completion will be provided to all other participants seeking continuing education credit from their specific accrediting organizations. Many accrediting organizations recognize the approval of ACCME PRA Category 1 credit; please note this activity has this type of approval. Disclosure Policies It is the policy of the National Osteoporosis Foundation to ensure balance, independence, objectivity, and scientific rigor in all sponsored publications and programs.  NOF requires disclosure of any significant financial interest or any other relationship that the Conference Planning Committee or Faculty members have with the manufacturer(s) of any commercial product(s) discussed in educational presentations.  All faculty and contributors to this continuing medical education activity have disclosed any real or apparent interest that may have direct bearing on the subject matter of this program.  Specific disclosure information will be included in the course handout materials. Click Here to Register Online Exhibits Exhibitor List Exhibitor Booth Number Alliance for Better Bone Health 500 American Academy of Orthopaedic Surgeons 419 American Orthopaedic Association 417 American Society of Bone & Mineral Research 507 Amgen, Inc. 400 Eli Lilly and Company 300 FDA Office of Women’s Health 418 Hologic, Inc. 501 International Society for Clinical Densitometry 518 Lone Oak Medical Technologies 309 Medtronic 409 National Association of Nurse Practitioners in Women’s Health 519 National Osteoporosis Foundation 315 NIH Osteoporosis and Related Bone Diseases 510 Novartis Pharmaceuticals 308 Optasia Medical 311 Osteoporosis Canada 218 Roche 408 Roche Diagnostics 410 Scanco     411 United States Bone and Joint Decade 313 Corportate Supporters Platinum Amgen Silver Eli Lilly Roche   Bronze Alliance for Better Bone Health Friend Wyeth Equal Opportunity Statement The National Osteoporosis Foundation is committed to equal opportunity and nondiscrimination in all programs and services, and does not discriminate on the basis of race/ethnicity, color, religion, sex, including marital status, national origin, ancestry, age, sexual orientation, disability, or veteran status. Americans with Disabilities Statement The National Osteoporosis Foundation in support of the spirit of the Americans with Disabilities Act (ADA), endeavors to honor all requests for reasonable accommodations in order for participants and/or members to achieve equal access to all programs and services. Liability Disclaimer Statement The National Osteoporosis Foundation shall not be held liable for personal injury, death, property damage or loss suffered by a participant in connection with any program or service, whether due to the negligence of staff or others. The National Osteoporosis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for  physicians.